Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter to the Editor
2018:84:6;706-707
doi: 10.4103/ijdvl.IJDVL_717_18
PMID: 30289120

‘End of the road for terbinafine’ in dermatophytosis: Is it a valid conclusion?

Rajsmita Bhattacharjee, Sunil Dogra
 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Sunil Dogra
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India
How to cite this article:
Bhattacharjee R, Dogra S. ‘End of the road for terbinafine’ in dermatophytosis: Is it a valid conclusion?. Indian J Dermatol Venereol Leprol 2018;84:706-707
Copyright: (C)2018 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

We read with keen interest the article by Singh and Shukla on the effectiveness of terbinafine in dermatophytosis, and wish to draw attention to some points.[1] There is no doubt that dermatophytosis has progressed from being an innocuous, easily treatable infection to one that is rapidly assuming gigantic proportions in India, with chronicity and multiple recurrences, although these terms have been only recently defined.[2] Drugs such as terbinafine that were uniformly effective in treating dermatophytosis earlier are now seldom proving so in the duration conventionally considered to be sufficient. However, to conclude regarding a mainstay agent as abysmally ineffective would require consideration of some pertinent issues.

In this prospective cohort study, 500 patients of dermatophytosis were included and treated with oral terbinafine (5 mg/kg/day) for a maximum duration of 4 weeks. The number of patients following up at the end of 2 and 4 weeks were 357 and 362 and the cure rates at these time points were found to be 2 and 30.6%, respectively. Out of 500 patients, 42% had applied topical corticosteroids in the recent past, either alone or in combination creams as over-the-counter topical preparations.[1] It is well known that the unregulated availability and use of such irrational corticosteroid–antifungal–antibacterial combinations causes a reduction in the local cellular immunity, thereby playing an important role in making the dermatophytosis notoriously recalcitrant.[3] In such a scenario, to confer the recalcitrance to merely lack of effectiveness of a hitherto effective drug, such as terbinafine, would seem as jumping the gun a little too soon; more so because the use of terbinafine in this study has not been compared with any other standard drug such as itraconazole in a parallel arm. In this study, of the total patients enrolled, 243 (48.6%) had already taken some form of oral and/or topical treatment and hence were not treatment-naïve cases. There is also a marked difference in the cure rates of dermatophytosis in this study at the end of 2 and 4 weeks from 2 to 30.6%. Hence, the use of terbinafine for a duration of 4 weeks is perhaps not adequate to determine its effectiveness in causing cure, and treatment longer than 4 weeks would have perhaps improved the cure rates much further. This seems particularly relevant in today's scenario where the conventional regimens of mainstream drugs such as terbinafine and azoles no longer seem effective in the durations prescribed in standard textbooks. In this regard, it is also useful to remember that it has been recommended that minimum duration of treatment should be 2–4 weeks in naïve cases and >4 weeks in recalcitrant cases.[2] The calculation of cure rates at the end of 4 weeks also seems fallacious (153 cured out of 362, giving a cure rate of 42.3% instead of 30.6% as mentioned in the article).

Two additional factors that do not seem to have been considered are the possibility of reinfection, because the family members were not screened; and information regarding demographic and socioeconomic variables and advice regarding hygiene were not provided. These, in all probability, could have played a role in determining the cure of infection with terbinafine. Recurrences may have been owing to reinfection from family members or the environment, or the duration of antifungal therapy given may be inadequate, as was the likely case in the index study. In a study on 150 patients of dermatophytosis from North India, the authors found high minimum inhibitory concentration (>2 μg/ml) for terbinafine in one Trichophyton interdigitale, four Trichophyton mentagrophytes and three Trichophyton rubrum isolates.[4] They concluded that increase in minimum inhibitory concentration is not the only factor responsible for recurrence and most of the strains were not drug-resistant, thereby further consolidating our point that the dismal cure rate of terbinafine may not be explained by its effectiveness alone.

Hence, we conclude that further well-designed studies comparing the effectiveness of terbinafine with other standard drugs, such as itraconazole, should be conducted before concluding that it is the end of the road for terbinafine.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol 2018;84:554-7.
[Google Scholar]
2.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol 2018;18:6.
[Google Scholar]
3.
Verma SB, Vasani R. Male genital dermatophytosis – Clinical features and the effects of the misuse of topical steroids and steroid combinations – An alarming problem in India. Mycoses 2016;59:606-14.
[Google Scholar]
4.
Pathania S, Rudramurthy SM, Narang T, Saikia UN, Dogra S. A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. Indian J Dermatol Venereol Leprol 2018 July (Epub ahead of print).
[Google Scholar]

Fulltext Views
443

PDF downloads
75
Show Sections